Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-1.95% | -8.87% |
2023 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
2023 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
More news
More press releases
More news
Manager | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 2018-08-31 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 2022-12-31 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 60 | 2014-12-31 |
Director | Title | Age | Since |
---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 45 | 2014-06-03 |
Eric Cornut
BRD | Director/Board Member | 68 | 2016-08-25 |
Günter von Au
CHM | Chairman | 74 | 2017-09-26 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-.--% | -1.95% | - | - | 5.73B | ||
-0.02% | +0.23% | +7.37% | +94.84% | 46.77B | ||
+0.79% | -2.43% | -3.70% | +36.59% | 23.82B | ||
+0.75% | +1.43% | +31.11% | - | 23.79B | ||
+0.11% | -1.70% | +0.20% | +59.28% | 14.01B | ||
-1.27% | -3.16% | -16.15% | +165.30% | 11.53B | ||
-2.89% | -4.92% | +66.48% | +69.11% | 6.99B | ||
+0.26% | +0.78% | +38.30% | +102.28% | 6.98B | ||
-.--% | +0.14% | - | - | 6.79B | ||
-0.72% | +3.60% | +33.99% | +369.01% | 6.02B | ||
Average | -0.32% | -0.69% | +19.70% | +128.06% | 15.24B | |
Weighted average by Cap. | -0.04% | -0.44% | +12.51% | +98.71% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Equities
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition